About Amedisys (NASDAQ:AMED)
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Debt
Debt-to-Equity Ratio0.14
Current Ratio1.63
Quick Ratio1.63
Price-To-Earnings
Trailing P/E Ratio38.44
Forward P/E Ratio27.36
P/E Growth1.45
Sales & Book Value
Annual Sales$1.53 billion
Price / Sales1.89
Cash Flow$2.8073 per share
Price / Cash30.31
Book Value$15.22 per share
Price / Book5.59
Profitability
EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins2.71%
Return on Equity16.83%
Return on Assets10.70%
Miscellaneous
Employees17,900
Outstanding Shares34,060,000
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings results on Monday, May, 7th. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.67 by $0.12. The health services provider earned $399.30 million during the quarter, compared to the consensus estimate of $395.38 million. Amedisys had a return on equity of 16.83% and a net margin of 2.71%. Amedisys's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.47 EPS. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys issued an update on its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share (EPS) guidance of $2.97-$3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.00. The company issued revenue guidance of $1.60-$1.64, compared to the consensus revenue estimate of $1.63 billion.
What price target have analysts set for AMED?
11 Wall Street analysts have issued 12-month target prices for Amedisys' shares. Their forecasts range from $56.00 to $82.00. On average, they anticipate Amedisys' share price to reach $69.60 in the next year. View Analyst Ratings for Amedisys.
Are investors shorting Amedisys?
Amedisys saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,303,655 shares, a decline of 26.0% from the May 15th total of 3,111,988 shares. Based on an average daily trading volume, of 232,824 shares, the short-interest ratio is currently 9.9 days. Approximately 6.9% of the company's stock are short sold.
Who are some of Amedisys' key competitors?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
- Mr. Michael P. North, Chief Information Officer (Age 53)
- Mr. Pete Hartley, Chief Technology Officer and Sr. VP of Bus. Operations Systems
Has Amedisys been receiving favorable news coverage?
Media stories about AMED stock have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a media sentiment score of 0.03 on Accern's scale. They also gave media stories about the health services provider an impact score of 46.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Amedisys' major shareholders?
Amedisys' stock is owned by many different of institutional and retail investors. Top institutional investors include KKR CREDIT ADVISORS (US) LLC (7.60%), Rhumbline Advisers (0.20%), O Shaughnessy Asset Management LLC (0.03%), Xact Kapitalforvaltning AB (0.01%) and SG Americas Securities LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Which major investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including O Shaughnessy Asset Management LLC. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.
Which major investors are buying Amedisys stock?
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $85.09.
How big of a company is Amedisys?
Amedisys has a market capitalization of $2.85 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
